MP69-06 THE ROLE OF EXTENDED OR SUPER-EXTENDED LYMPH NODE DISSECTION FOR STAGING OF HIGH-RISK PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy V1 Apr 2016MP69-06 THE ROLE OF EXTENDED OR SUPER-EXTENDED LYMPH NODE DISSECTION FOR STAGING OF HIGH-RISK PROSTATE CANCER Lorenzo Tosco, Sofie Isebaert, Evelyne Lerut, Wouter Everaerts, Maarten Albersen, Laura Van den Bergh, Christophe Deroose, Karolien Goffin, Karin Haustermans, Hein Van Poppel, and Steven Joniau Lorenzo ToscoLorenzo Tosco More articles by this author , Sofie IsebaertSofie Isebaert More articles by this author , Evelyne LerutEvelyne Lerut More articles by this author , Wouter EveraertsWouter Everaerts More articles by this author , Maarten AlbersenMaarten Albersen More articles by this author , Laura Van den BerghLaura Van den Bergh More articles by this author , Christophe DerooseChristophe Deroose More articles by this author , Karolien GoffinKarolien Goffin More articles by this author , Karin HaustermansKarin Haustermans More articles by this author , Hein Van PoppelHein Van Poppel More articles by this author , and Steven JoniauSteven Joniau More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1384AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The role of pelvic lymph node (PLND) dissection for treatment of high-risk prostate cancer is still debated particularly for extensive surgical procedures. To assess the reliability of ePLND as standard staging procedure and the potential benefit of sePLND high-risk prostate cancer. METHODS Between 2006 and 2015 471 consecutive patients were treated by open radical prostatectomy (RP) and PLND with different template extensions for treatment of high-risk prostate cancer (cT=3a and/or PSA>20ng/ml and/or biopsy Gleason score =8) in a single institution. During the surgical procedures the pelvic N were dissected and sent to pathology as separate anatomical areas as routine procedure. Extended e-PLND included fibro-fatty tissue in the obturator fossa, on the surface of external and internal iliac vessels. Super-ePLND included also common iliac and presacral areas. Lymph node areas outside of these templates were excluded from the analyses. Other exclusion criteria were PLND packages not defined per anatomical areas, missing data. Descriptive statics were specifically applied. RESULTS After the application of the exclusion criteria 116 sePLND patients remained for analysis. After sePLND 3508 N were removed and 4%(147) resulted positive in 42%(49) patients. N mapping for each template is shown on Table 1. The density of positive N per total number of N removed per region was respectively: 3%(17) common iliac, 4%(33) external iliac, 7%(45) internal iliac, 3%(36) obturator, 4%(16) presacral. The proportions of patients with positive nodes per template assuming sePLND as reference are shown on Table 1 as the proportions of positive nodes detected per template. CONCLUSIONS ePLND represents a reliable staging procedure in high risk prostate cancer with the majority of positive nodes found in the internal iliac region. 96% of patients with positive nodes are correctly staged in case a standard ePLND and sePLND should be tailored for selected patients. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e899-e900 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Lorenzo Tosco More articles by this author Sofie Isebaert More articles by this author Evelyne Lerut More articles by this author Wouter Everaerts More articles by this author Maarten Albersen More articles by this author Laura Van den Bergh More articles by this author Christophe Deroose More articles by this author Karolien Goffin More articles by this author Karin Haustermans More articles by this author Hein Van Poppel More articles by this author Steven Joniau More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...